Alnylam Pharmaceuticals, Inc. is an independent biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. These medicines work by silencing genes that contribute to diseases, offering a novel approach to treatment. Alnylam has developed several RNAi therapeutics approved for use, targeting both rare and prevalent diseases. The company operates primarily in the biopharmaceutical sector and serves patients globally, leveraging its expertise in genetic medicine to address various health conditions.
